



# BURZYNSKI

RESEARCH INSTITUTE, INC.

March 29, 1995

Michael A. Friedman, M.D.  
Associate Director  
Cancer Therapy Evaluation Program  
Division of Cancer Treatment, NCI  
National Institutes of Health  
6130 Executive Plaza North, Room 742  
Bethesda, MD 20892

Dear Dr. Friedman,

It has been brought to my attention that the protocol for "Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Advanced Recurrent Malignant Astrocytomas" has been amended to accept patients with tumors measuring over 5 cm in diameter, multiple tumors, or with leptomeningeal or systemic metastases. Another change involves lowering of the Karnofsky Performance Status score to 60%.

You assured me in your letter of November 2, 1993 that "The dose and schedule will be modified exactly as you require" and "The eligibility criteria will be modified to accept only patients with Karnofsky Performance Status of 70% - 100%."

I am outraged that without my knowledge Memorial Sloan-Kettering Cancer Center with NCI's permission changed the protocol. Treatment of patients with tumors larger than 5 cm, with multiple tumors, and leptomeningeal spread or distant metastases will require a different protocol with a different schedule and different dosages. The use of the existing protocol for such very advanced brain tumor patients will only expose them to unnecessary risks without giving them substantial benefit.

I hereby request that the amendments described above be cancelled immediately and the original protocol be used for the treatment as promised in your letter of November 2, 1993. We will be glad to propose a different protocol for patients with larger and multiple tumors and meningeal involvement.

In addition, the procedure we agreed upon calls for a thorough review by us of data from the first five patients as soon as they are accrued. Your last annual report indicates

that you had accrued that number of patients six months ago. As a result, the review of data is long overdue. Please send us the complete records of the first five patients so that we may review them as specified. Please do not accrue any more patients until this data has been sent and our review completed.

Sincerely,



S. R. Burzynski, M.D., Ph.D.

SRB/cf

cc:

Dr. Jan Bruckner  
Dr. Michael C. Christian  
Dr. Jay Greenblatt  
Dr. Mark Malkin  
Ms. Mary McCabe  
Dr. David Parkinson  
Dr. Mario Sznol  
Ms. Dorothy Tisevich